Ministry of Health

Justice served in secret is a dangerous precedent: Quebec criminal court system under spotlight for holding 'phantom trial'

Retrieved on: 
Tuesday, June 13, 2023

Further, there was also no information available about the date or location of the trial or details on the charges.

Key Points: 
  • Further, there was also no information available about the date or location of the trial or details on the charges.
  • In March 2022, media organizations across the province issued an open letter expressing their "indignation" and "deep concern" with the secret trial.
  • "The open court principle was egregiously violated here, undermines public confidence in the integrity of the court system, creating suspicion and rendering public oversight of what happened behind closed doors impossible."
  • In response to the news, Quebec's justice minister, Simon Jolin-Barrette , said he had held discussions with the Superior Court and the Quebec court and that secret trials would not happen again.

Astellas Submits New Drug Application for Zolbetuximab in Japan

Retrieved on: 
Friday, June 9, 2023

TOKYO, June 9, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the submission of a New Drug Application (NDA) on June 9, 2023 to Japan's Ministry of Health, Labour and Welfare (MHLW) for zolbetuximab, a first-in-class investigational Claudin 18.2 (CLDN18.2)-targeted monoclonal antibody, for first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2-positive. If approved, zolbetuximab would be the first CLDN18.2-targeted therapy available in Japan for these patients.

Key Points: 
  • If approved, zolbetuximab would be the first CLDN18.2-targeted therapy available in Japan for these patients.
  • "Astellas' submission of a New Drug Application to Japan's Ministry of Health, Labour and Welfare for zolbetuximab demonstrates critical momentum in addressing the unmet needs of patients with gastric cancer in Japan."
  • The SPOTLIGHT study evaluated zolbetuximab plus mFOLFOX6 (a combination regimen that includes oxaliplatin, leucovorin and fluorouracil) compared to placebo plus mFOLFOX6.
  • The GLOW study evaluated zolbetuximab plus CAPOX (a combination chemotherapy regimen that includes capecitabine and oxaliplatin) compared to placebo plus CAPOX.

Orbis and partners mark historic 100 millionth dose of sight-saving antibiotic azithromycin in the fight to eliminate blinding trachoma in Ethiopia by 2030

Retrieved on: 
Tuesday, May 16, 2023

NEW YORK, May 16, 2023 /PRNewswire/ -- Eye care nonprofit Orbis International today announced that it has distributed 100 million doses of azithromycin antibiotics in Ethiopia. This is part of ongoing efforts to eliminate trachoma, an infectious, painful, and blinding eye disease, by 2030, in line with World Health Organization goals.

Key Points: 
  • This is part of ongoing efforts to eliminate trachoma, an infectious, painful, and blinding eye disease, by 2030, in line with World Health Organization goals.
  • Local children performed a play during a celebration to mark the moment, and community leaders blessed the giving of the historic dose.
  • So, while the work continues, today has a special meaning to all involved in working to eliminate trachoma in Ethiopia."
  • In 2022, Orbis and its partners distributed 3.4 million antibiotic doses for trachoma control and elimination within Ethiopia.

Global and Regional Surgical Robotics Market Analysis and Forecasts, 2022-2023 & 2032 - ResearchAndMarkets.com

Retrieved on: 
Friday, April 28, 2023

The "Surgical Robotics Market - A Global and Regional Analysis: Focus on Type, Application, End-user, and Country - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Surgical Robotics Market - A Global and Regional Analysis: Focus on Type, Application, End-user, and Country - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering.
  • The increasing demand for minimally invasive surgeries, increasing demand for robotic-assisted surgeries, and increasing synergetic activities within the surgical robotics industry are some of the major opportunities in the global surgical robotics market.
  • The COVID-19 pandemic has impacted practically all sectors and social functions worldwide, including the global surgical robotics market.
  • The global surgical robotics market based on the end-user segment is dominated by the hospitals segment.

Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma

Retrieved on: 
Monday, April 17, 2023

The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of December 16, 2023.

Key Points: 
  • The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of December 16, 2023.
  • Data from KarMMa-3 were published in The New England Journal of Medicine on February 10, 2023.
  • In addition, Japan's Ministry of Health, Labour and Welfare has accepted Bristol Myers Squibb’s supplemental New Drug Application (sNDA) for Abecma based on the KarMMa-3 study.
  • Abecma is also approved in the European Union, Switzerland, the United Kingdom, Japan, Canada, and Israel for adult patients with triple-class exposed relapsed and/or refractory multiple myeloma after three to four or more prior lines of therapy.

BGI Genomics Partners with Zentya to Launch Fecal DNA Test for Colorectal Cancer in Slovakia

Retrieved on: 
Wednesday, March 29, 2023

BRATISLAVA, Slovakia, March 29, 2023 /PRNewswire/ -- BGI Genomics is pleased to announce the launch of COLOTECTTM 1.0 in Slovakia, in collaboration with its partner, Zentya.

Key Points: 
  • BRATISLAVA, Slovakia, March 29, 2023 /PRNewswire/ -- BGI Genomics is pleased to announce the launch of COLOTECTTM 1.0 in Slovakia, in collaboration with its partner, Zentya.
  • COLOTECTTM 1.0 is one of the first-ever fecal DNA tests for colorectal cancer that is available in Slovakia.
  • It is a non-invasive fecal DNA test for detecting colorectal cancer and precancerous lesions.
  • Early detection is the key to the prevention of colorectal cancer and the improvement of survival rate because the progression of colorectal cancer development is generally very slow.

Biomeme Supports Biosecurity Surveillance Program Launched by Ginkgo Bioworks and the Ukraine Ministry of Health

Retrieved on: 
Monday, March 20, 2023

PHILADELPHIA, March 20, 2023 /PRNewswire-PRWeb/ -- Ginkgo Bioworks and the Public Health Center of the Ukraine Ministry of Health announced the launch of a pilot program for wastewater-based pathogen monitoring, in partnership with Biomeme. The goal of this program is to provide continuous data on infectious pathogens, such as SARS-CoV-2 and influenza, to minimize the impact of infectious diseases on the people of Ukraine. This program complements Biomeme's expanding range of biosecurity testing solutions, including the identification of biowarfare agents, infectious diseases, industrial hygiene, and environmental health CONOPs.

Key Points: 
  • Ginkgo Bioworks and the Public Health Center of the Ukraine Ministry of Health announced the launch of a pilot program for wastewater-based pathogen monitoring in partnership with Biomeme.
  • PHILADELPHIA, March 20, 2023 /PRNewswire-PRWeb/ -- Ginkgo Bioworks and the Public Health Center of the Ukraine Ministry of Health announced the launch of a pilot program for wastewater-based pathogen monitoring , in partnership with Biomeme.
  • This program complements Biomeme's expanding range of biosecurity testing solutions, including the identification of biowarfare agents, infectious diseases, industrial hygiene, and environmental health CONOPs.
  • Concentric by Ginkgo, Ginkgo Bioworks' biosecurity and public health unit, has partnered with the Ukraine Ministry of Health to design a practical solution for monitoring biological threats found in critical wastewater systems, including sewage systems and natural waterways.

Eisai Receives the "Basic Achievement Grand Prize" at the 2023 J-Win Diversity Award

Retrieved on: 
Friday, March 10, 2023

TOKYO, Mar 10, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it was selected as the winner of the "Basic Achievement Grand Prize" at the "2023 J-Win Diversity Award" held by non-profit organization Japan Women's Innovative Network (NPO J-Win).

Key Points: 
  • TOKYO, Mar 10, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it was selected as the winner of the "Basic Achievement Grand Prize" at the "2023 J-Win Diversity Award" held by non-profit organization Japan Women's Innovative Network (NPO J-Win).
  • The "J-Win Diversity Award" has been held annually since 2008 with the aim of accelerating the promotion of diversity and inclusion (D&I) in Japanese companies by awarding leading businesses that are promoting D&I.
  • - Plans to introduce a new personnel assessment system from FY 2023, which utilizes a behavioral assessment item "Diversity & Synergy" to further focus on diversity.
  • Eisai aims to realize the spiral of knowledge generated by diversity, regardless of differences in nationality, gender, age, etc., leading to the creation of innovation.

SciSparc Successfully Completed Production of its Proprietary Drug Candidate SCI-110 for its Upcoming Clinical Trial On Tourette Syndrome

Retrieved on: 
Monday, March 6, 2023

The Company has already received ethics committee approvals from the Hannover Medical School in Hannover, Germany, and the Tel Aviv Sourasky Medical Center, in Tel Aviv, Israel.

Key Points: 
  • The Company has already received ethics committee approvals from the Hannover Medical School in Hannover, Germany, and the Tel Aviv Sourasky Medical Center, in Tel Aviv, Israel.
  • The Company is currently preparing to submit a request for approval to the Institutional Review Board of Yale University, Connecticut, USA (“Yale’s IRB”).
  • Tics may be associated with a premonitory sensation to perform a specific action, which may lead to “relief” once performed.
  • “With the successful manufacturing of the clinical batches, we are one step closer to initiate this important clinical trial.”

Mexico Needs mpox Vaccine, Says AHF and Vaccine Advocates in The Lancet Letter

Retrieved on: 
Wednesday, March 8, 2023

The European Medicines Agency and the US FDA have also authorized the use of the vaccine.

Key Points: 
  • The European Medicines Agency and the US FDA have also authorized the use of the vaccine.
  • Among the authors of this study is the highest decision-maker in public health in Mexico, Dr. Hugo López-Gatell, Undersecretary of Health.
  • The letter was accepted and finally published by the same magazine in its correspondence section titled " MPOX vaccines are needed in Mexico ,” on March 6, 2023.
  • To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare .